Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Broadens Diovan Heart Failure Indication Based On Atacand Clinical Data

Aug 08 2005

• By The Pink Sheet

Related Content

Antihypertensive Cardio Labeling Should Be Applied To New Classes – Cmte.

Jun 27 2005

Novartis’ VALIANT Effort: Diovan Gains Post-Myocardial Infarction Indication

Aug 08 2005

Atacand Approval Provides Alternative To ACE Inhibitors For Heart Failure

Feb 28 2005

Aventis Merger Would Bring New Blood To Novartis’ Cardiology R&D

Apr 05 2004

Merck Cozaar, Bristol Avapro Gain Nephropathy Indication On Shared Data

Sep 23 2002

Novartis Diovan Gets Heart Failure Claim But Is Second Line To ACE Inhibitors

Aug 19 2002

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window